Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Zhaoyu Jin, Ph.D
CONTACT
Lead
FutureGen Biopharmaceutical (Beijing) Co., Ltd
This is a multicenter, randomized, double-blind, placebo-controlled phase 3 study designed to evaluate the efficacy and safety of FG-M108 injection combined with Nab-P+GEM versus placebo combined with Nab-P+GEM as first-line treatment in patients with Claudin18.2-positive, unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted